doi: 10.1021/jm800401t.
Epub 2008 Jun 14.
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Affiliations
- PMID: 18553959
- DOI: 10.1021/jm800401t
Item in Clipboard
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
J Med Chem.
.
Abstract
Deregulation of the receptor tyrosine kinase c-Met has been implicated in human cancers. Pyrazolones with N-1 bearing a pendent hydroxyalkyl side chain showed selective inhibition of c-Met over VEGFR2. However, studies revealed the generation of active, nonselective metabolites. Blocking this metabolic hot spot led to the discovery of 17 (AMG 458). When dosed orally, 17 significantly inhibited tumor growth in the NIH3T3/TPR-Met and U-87 MG xenograft models with no adverse effect on body weight.
Similar articles
-
Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.J Med Chem. 2012 Mar 8;55(5):1868-97. doi: 10.1021/jm201331s. Epub 2012 Feb 24. J Med Chem. 2012. PMID: 22320327
-
Chemical reactivity of methoxy 4-o-aryl quinolines: identification of glutathione displacement products in vitro and in vivo.Chem Res Toxicol. 2008 Nov;21(11):2216-22. doi: 10.1021/tx800307n. Chem Res Toxicol. 2008. PMID: 18837519
-
Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily.J Med Chem. 2009 Mar 12;52(5):1251-4. doi: 10.1021/jm801586s. J Med Chem. 2009. PMID: 19260711
-
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.Clin Cancer Res. 2009 Apr 1;15(7):2207-14. doi: 10.1158/1078-0432.CCR-08-1306. Epub 2009 Mar 24. Clin Cancer Res. 2009. PMID: 19318488 Review.
-
Drug development of MET inhibitors: targeting oncogene addiction and expedience.Nat Rev Drug Discov. 2008 Jun;7(6):504-16. doi: 10.1038/nrd2530. Nat Rev Drug Discov. 2008. PMID: 18511928 Review.
Cited by
-
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.J Hematol Oncol. 2022 Jul 7;15(1):89. doi: 10.1186/s13045-022-01310-7. J Hematol Oncol. 2022. PMID: 35799213 Free PMC article. Review.
-
Ionic Liquids Immobilized Synthesis of New Xanthenes Derivatives and their Antiproliferative, Molecular Docking, and Morphological Studies.Anticancer Agents Med Chem. 2024;24(13):990-1008. doi: 10.2174/0118715206299407240324110505. Anticancer Agents Med Chem. 2024. PMID: 38685778
-
Spatially restricted Hedgehog signalling regulates HGF-induced branching of the adult prostate.Nat Cell Biol. 2014 Dec;16(12):1135-45. doi: 10.1038/ncb3057. Epub 2014 Nov 2. Nat Cell Biol. 2014. PMID: 25362352 Free PMC article.
-
Design, synthesis, and biological evaluation of thiazole/thiadiazole carboxamide scaffold-based derivatives as potential c-Met kinase inhibitors for cancer treatment.J Enzyme Inhib Med Chem. 2023 Dec;38(1):2247183. doi: 10.1080/14756366.2023.2247183. J Enzyme Inhib Med Chem. 2023. PMID: 37642355 Free PMC article.
-
Applications of palladium-catalyzed C-N cross-coupling reactions in pharmaceutical compounds.RSC Adv. 2023 Jun 20;13(27):18715-18733. doi: 10.1039/d2ra07412e. eCollection 2023 Jun 15. RSC Adv. 2023. PMID: 37346956 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous
